Rohto Dry Aid, a new over-the-counter (OTC) lubricant eye drop was found to show superior relief of discomfort associated with visual tasking activities, and may provide a longer duration of symptomatic relief over the course of a day, compared to another widely-used ocular lubricant, according to a study published in the peer-reviewed journal Clinical Ophthalmology.1
This prospective, single center, parallel group study, sponsored by The Mentholatum Company, marketer of Rohto Dry Aid, compared the effects of Rohto Dry Aid versus a leading artificial tear brand in the United States in patients 18 years of age or older (n= 80) diagnosed with mild-to-moderate dry eye disease (DED) over approximately 30 days in a real-life, real-time setting. Subjects were assigned to one of the two products, and were monitored at 2- and 4-weeks during the course of the study. All subjects completed the entire 30-day duration.
“A key to the study design was that it represented an assessment conducted in a real-life, real-time setting rather than a strictly clinic-based trial,” study co-author Parag A. Majmudar, MD, President and Chief Medical Officer, Chicago Cornea Consultants, said in a company news release. “For this reason, it may provide a more realistic picture as to its relative effectiveness compared to traditional dry eye therapies.”
Results were assessed based upon comparisons to baseline measures and on direct comparisons between the two products at specified time-points. Efficacy endpoints included corneal fluorescein staining, lissamine staining, visual function tests, ocular discomfort, diary discomfort scales, and the Ocular Surface Disease Index measurements.
Ocular comfort scores confirmed that both products provide an immediate, significant improvement in ocular comfort that was sustained for at least 1 hour after instillation. However, patients using Rohto Dry Aid (n=40) reported longer lasting relief of the ocular signs, symptoms, and visual function issues associated with DED versus the comparator product.
“One of the most intriguing distinctions between the two products was observed in diary data that showed Rohto Dry Aid mean scores for ocular discomfort and dryness remained approximately the same from morning to evening while the comparator product mean scores in these two areas trended upward from morning to evening,” co-author Michael S. Cooper, OD, Windham Eye Group, P.C., Willimantic, Conn., said in the news release. "Patient-reported symptoms from this study suggest that Rohto Dry Aid balances the ocular surface throughout the day, which may help reduce patients’ need for continuous dosing and allow for improved quality of life and visual measures.”
At each study visit, subjects were also queried using the Ora Calibra Quality of Life Questionnaire, which includes questions addressing visual function as well as other symptom assessments. Only the Rohto Dry Aid group reported significant improvements in comfort scores during visual tasking activities such as television or movie viewing and driving at night.
“Studies consistently show that DED has a measureable impact on several aspects of patients’ Quality of Life, including their ability to perform certain activities requiring sustained visual attention (e.g. reading, driving),” said Dr. Majmudar. “Data from this study suggests that Rohto Dry Aid provides superior relief of discomfort associated with visual tasking activities.”